Inclusion Criteria:

        Tumor Type

          -  Unresectable low-grade gliomas that have received at least two chemotherapy/biologic
             regimens. Radiation therapy counts as a biologic regimen. Patients may not have
             received radiation therapy to the index lesion within 1 year of enrollment. Patients
             may have tumor spread within the central nervous system (CNS).

          -  HLA-A2 positive based on flow cytometry.

          -  Patients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day,
             max 4 mg/day Dexamethasone) corticosteroid for at least one week prior to study
             registration.

          -  Patients must be ≥ 12 months and < 22 years of age at the time of HLA-A2 screening.

          -  Patients must have a performance status of ≥ 70; (Karnofsky if > 16 years and Lansky
             if ≤ 16 years of age.

          -  Documented negative serum beta-human chorionic gonadotropin (HCG) for female patients
             who are post-menarchal. Because the effect of the peptide-based vaccine and poly-ICLC
             on the fetus has not sufficiently been investigated, pregnant females will not be
             included in the study.

          -  Patients must be free of systemic infection requiring IV antibiotics at the time of
             registration. Patients must be off IV antibiotics for at least 7 days prior to
             registration.

          -  Patients with adequate organ function as measured by: Bone marrow: absolute neutrophil
             count (ANC) > 1,000/µ; Platelets > 100,000/µ (transfusion independent); absolute
             lymphocyte count of ≥ 500/µ; Hemoglobin >8 g/dl (may be transfused). Hepatic:
             bilirubin < 1.5x institutional normal for age; serum glutamate pyruvate transaminase
             (SGPT) < 3x institutional normal.

          -  Renal: Serum creatinine based on age or Creatinine clearance or radioisotope
             glomerular filtration rate (GFR) ≥ 70 ml/min/ml/min/1.73 m²

          -  Patients must have recovered from the toxic effects of prior therapy to grade 1 or
             better. Patients must be at least 3 weeks from the last dose of standard cytotoxic
             chemotherapy or myelosuppressive biological therapy and at least 1 week from the last
             dose of non-myelosuppressive biologic therapy.

          -  No overt cardiac, gastrointestinal, pulmonary or psychiatric disease.

        Exclusion Criteria:

          -  Patients living outside of North America are not eligible.

          -  Patients may not have received radiation to the index lesion within 1 year of
             enrollment.

          -  Concurrent treatment or medications (must be off for at least 1 week) including:

               -  Interferon (e.g. Intron-A®)

               -  Allergy desensitization injections

               -  Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)

               -  Interleukins (e.g. Proleukin®)

               -  Any investigational therapeutic medication

          -  Patients must not have a history of, or currently active autoimmune disorders
             requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with
             visceral involvement.

          -  Use of immunosuppressives within four weeks prior to study entry or anticipated use of
             immunosuppressive agents. Dexamethasone, or other corticosteroid medications, if used
             in the peri-operative period must be tapered to no more than 0.1 mg/kg/day, max 4
             mg/day dexamethasone for at least one week before study registration. Topical
             corticosteroids are acceptable.

          -  Because patients with immune deficiency are not expected to respond to this therapy,
             HIV-positive patients are excluded from the study.

          -  Patients who have received prior immunotherapy.